Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Sees Large Growth in Short Interest

Basilea Pharmaceutica AG (OTCMKTS:BPMUF) saw a significant growth in short interest in May. As of May 29th, there was short interest totaling 1,171 shares, a growth of 114.5% from the May 14th total of 546 shares. Based on an average daily volume of 2 shares, the days-to-cover ratio is currently 585.5 days. Currently, 0.0% of the shares of the stock are sold short.

Basilea Pharmaceutica Price Performance

Shares of OTCMKTS BPMUF remained flat at $60.28 during midday trading on Friday. Basilea Pharmaceutica has a 1 year low of $59.29 and a 1 year high of $74.00. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.68 and a current ratio of 5.11. The company has a 50-day moving average price of $67.58 and a two-hundred day moving average price of $67.81.

About Basilea Pharmaceutica

Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital?treated diseases. The company’s research is focused primarily on anti?infectives and oncology, with a portfolio that spans both marketed products and early? to late?stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.

Among its lead products is isavuconazole, a broad?spectrum antifungal agent marketed under the trade name Cresemba.